Companies Verve Therapeutics, Inc.
Verve Therapeutics (VERV): executive pay, fiscal 2024
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Verve Therapeutics, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $7,846,718FY2022
- $9,319,782FY2023
- $7,442,663FY2024
CEO total pay was $7,442,663 in fiscal 2024, down from $9,319,782 in fiscal 2023.
FY2024: salary $639,231 · bonus $0 · stock awards $1,683,000 · option awards $4,727,372
Executives and directors
Andrew Ashe · PresidentAndrew Bellinger · Chief Scientific OfficerAllison Dorval · CFOSekar Kathiresan · CEOAlexander Cumbo · Independent DirectorBurt Adelman, M.D · Chair of the BoardJodie Morrison · Independent DirectorKrishna Yeshwant, M.D · Independent DirectorLonnel Coats · Independent DirectorMichael MacLean · Independent DirectorOurania Tatsis, Ph.D · DirectorSheila Mikhail, J.D · Independent Director
Frequently asked questions
Who was the highest-paid executive at Verve Therapeutics, Inc. in fiscal 2024?
As disclosed, Sekar Kathiresan (Chief Executive Officer) was the highest-paid executive at Verve Therapeutics, Inc. in fiscal 2024, with total compensation of $7,442,663.
How did shareholders vote on Verve Therapeutics, Inc.'s executive compensation?
As disclosed, 95.33% of shareholders supported Verve Therapeutics, Inc.'s executive compensation in the latest say-on-pay vote.
How much does Verve Therapeutics, Inc. spend in total on board compensation for fiscal 2024?
As disclosed, Verve Therapeutics, Inc. reported total board compensation of $408,139 for fiscal 2024.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Sekar Kathiresan | $639,231 | $0 | $1,683,000 | $4,727,372 | $378,972 | $0 | $14,088 | $7,442,663 |
| Chief Executive Officer | ||||||||
| Andrew Bellinger | 243,846 | 0 | 573,750 | 2,038,946 | 0 | 0 | 574,358 | 3,430,900 |
| Former Chief Scientific Officer | ||||||||
| Allison Dorval | 469,423 | 0 | 573,750 | 1,617,732 | 206,712 | 0 | 14,088 | 2,881,705 |
| Chief Financial Officer | ||||||||
| Andrew Ashe | 389,077 | 0 | 459,000 | 1,348,110 | 172,260 | 0 | 11,618 | 2,380,065 |
| President, Chief Operating Officer and General Counsel | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Sekar Kathiresan | $7,442,663 | $9,319,782 | $7,846,718 | ↓ −1,877,119 |
| Andrew Bellinger | 3,430,900 | 3,531,364 | 3,319,498 | ↓ −100,464 |
| Allison Dorval | 2,881,705 | 3,484,839 | — | ↓ −603,134 |
| Andrew Ashe | 2,380,065 | — | 3,319,498 | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
equity grants provide our executives with a strong link to our long-term performance, create an ownership culture and help to align the interests of our executives and our stockholders
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Radford Data & Analytics from Aon plc |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2024
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Andrew Ashe | OPTION | — | — | — | — | — | $1,348,110 |
| Andrew Bellinger | OPTION | — | — | — | — | — | 2,038,946 |
| Sekar Kathiresan | PSU | — | — | — | — | — | 1,683,000 |
| Sekar Kathiresan | OPTION | — | — | — | — | — | 4,727,372 |
| Allison Dorval | PSU | — | — | — | — | — | 573,750 |
| Andrew Bellinger | PSU | — | — | — | — | — | 573,750 |
| Allison Dorval | OPTION | — | — | — | — | — | 1,617,732 |
| Andrew Ashe | PSU | — | — | — | — | — | 459,000 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Andrew Ashe | $0 | $459,000 | $1,348,110 | 25.4% |
| Andrew Bellinger | 0 | 573,750 | 2,038,946 | 22.0% |
| Sekar Kathiresan | 0 | 1,683,000 | 4,727,372 | 26.3% |
| Allison Dorval | 0 | 573,750 | 1,617,732 | 26.2% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2024
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Allison Dorval | RSU | 1,875 | — | $10,575 |
| Andrew Ashe | Option | 2,700 | 19 | — |
| Andrew Ashe | Option | 4,500 | 8.24 | — |
| Sekar Kathiresan | Option | 6,750 | 19 | — |
| Allison Dorval | Option | 17,500 | 30.94 | — |
| Sekar Kathiresan | Option | 18,000 | 8.24 | — |
| Allison Dorval | Option | 30,943 | 33.25 | — |
| Andrew Ashe | RSU | 36,000 | — | 203,040 |
| Andrew Ashe | Option | 36,459 | 30.94 | — |
| Allison Dorval | RSU | 45,000 | — | 253,800 |
| Sekar Kathiresan | Option | 96,838 | 30.94 | — |
| Andrew Ashe | Option | 99,015 | 21.76 | — |
| Allison Dorval | Option | 99,015 | 21.76 | — |
| Sekar Kathiresan | RSU | 132,000 | — | 744,480 |
| Andrew Ashe | Option | 150,000 | 12.75 | — |
| Allison Dorval | Option | 180,000 | 12.75 | — |
| Sekar Kathiresan | Option | 298,014 | 21.76 | — |
| Sekar Kathiresan | Option | 526,000 | 12.75 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Jodie MorrisonIndependent · Compensation · Research and Development · Newly elected | $26,971 | $0 | $937,999 | $0 | $0 | $964,970 |
| Burt Adelman, M.DIndependent · Board Chair · Compensation (Chair) · Nominating/Governance (Chair) | 100,000 | 0 | 468,999 | 0 | 0 | 568,999 |
| Michael MacLeanIndependent · Audit (Chair) | 65,000 | 0 | 468,999 | 0 | 0 | 533,999 |
| Sheila Mikhail, J.DIndependent · Audit · Nominating/Governance | 57,500 | 0 | 468,999 | 0 | 0 | 526,499 |
| Krishna Yeshwant, M.DIndependent · Nominating/Governance | 53,668 | 0 | 468,999 | 0 | 0 | 522,667 |
| Lonnel CoatsIndependent · Audit | 52,500 | 0 | 468,999 | 0 | 0 | 521,499 |
| Alexander CumboIndependent · Compensation | 52,500 | 0 | 468,999 | 0 | 0 | 521,499 |
| Sekar Kathiresan, M.DEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Ourania Tatsis, Ph.DNot independent · Research and Development (Chair) · Newly elected | — | 0 | — | 0 | 0 | — |
Board fee structure and ownership guideline
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | $170,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 12,500 / 7,500 / 5,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $408,139 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $408,139 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Verve Therapeutics as a peer
Companies that benchmark against VERV
9 companies name VERV as a compensation peer
- AbCellera Biologics Inc.ABCLFY2025
- Atrium Therapeutics, Inc.RNAFY2024
- Avidity Biosciences, Inc.RNAMFY2024
- Beam Therapeutics Inc.BEAMFY2025
- D-Wave Quantum, Inc.QBTSFY2025
- Generation Bio Co.GBIOFY2024
- Intellia Therapeutics, Inc.NTLAFY2025
- uniQure N.V.QUREFY2025
- Voyager Therapeutics, Inc.VYGRFY2025
- Wave Life Sciences, Inc.WVEFY2025
Each company listed discloses VERV in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named VERV in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Verve Therapeutics, Inc. | 2024 | Sekar Kathiresan | $639,231 | $1,683,000 | $4,727,372 | $378,972 | $7,442,663 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-06-05 | 56,159,136 | 2,748,937 | 478,381 | 95.33% | Passed |
| 2024 | 2024-06-06 | 39,396,050 | 5,481,524 | 25,644 | 87.79% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2025 | 2025-06-05 | 95.33%a |
| 2024 | 2024-06-06 | 87.79%b |
a. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be counted as votes cast or voted on Proposals No.”.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be counted as votes cast or voted on Proposals No.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Krishna Yeshwant | Director | 2025-06-05 | A | 42,200 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Alexander Cumbo | Director | 2025-06-05 | A | 42,200 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sheila Mikhail | Director | 2025-06-05 | A | 42,200 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jodie Morrison | Director | 2025-06-05 | A | 42,200 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael MacLean | Director | 2025-06-05 | A | 42,200 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Burt A. Adelman | Director | 2025-06-05 | A | 42,200 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lonnel Coats | Director | 2025-06-05 | A | 42,200 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ourania Tatsis | Director | 2025-06-05 | A | 42,200 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jason Politi | Chief Technical Ops. Off. | 2025-07-25 | D | 90,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jason Politi | Chief Technical Ops. Off. | 2025-07-25 | D | 16,405 | — | — | Common | Form 4 ↗ |
| Andrew Ashe | See Remarks | 2025-07-25 | D | 150,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andrew Ashe | See Remarks | 2025-07-25 | D | 40,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andrew Ashe | See Remarks | 2025-07-25 | D | 225,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andrew Ashe | See Remarks | 2025-07-25 | D | 348,828 | — | — | Common | Form 4 ↗ |
| Sekar Kathiresan | Director | 2025-07-25 | D | 75,105 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sekar Kathiresan | Director | 2025-07-25 | D | 138,995 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sekar Kathiresan | Director | 2025-07-25 | D | 240,997 | — | — | Common | Form 4 ↗ |
| Joan Nickerson | Chief Administrative Officer | 2025-07-25 | D | 225,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Allison Dorval | Chief Financial Officer | 2025-07-25 | D | 13,280 | — | — | Common | Form 4 ↗ |
| Andrew Ashe | See Remarks | 2025-07-25 | D | 27,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jason Politi | Chief Technical Ops. Off. | 2025-07-25 | D | 225,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sekar Kathiresan | Director | 2025-07-25 | D | 167,425 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ourania Tatsis | Director | 2025-07-25 | D | 267,541 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jason Politi | Chief Technical Ops. Off. | 2025-07-25 | D | 118,796 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andrew Ashe | See Remarks | 2025-07-25 | D | 26,999 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Troy Lister | Chief Scientific Officer | 2025-07-25 | D | 32,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Troy Lister | Chief Scientific Officer | 2025-07-25 | D | 40,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sekar Kathiresan | Director | 2025-07-25 | D | 431,988 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Joan Nickerson | Chief Administrative Officer | 2025-07-25 | D | 125,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Joan Nickerson | Chief Administrative Officer | 2025-07-25 | D | 6,630 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Joan Nickerson | Chief Administrative Officer | 2025-07-25 | D | 17,420 | — | — | Common | Form 4 ↗ |
| Krishna Yeshwant | Director | 2025-07-25 | D | 136,139 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Krishna Yeshwant | Director | 2025-07-25 | D | 6,108,442 | — | — | Common, indirect | Form 4 ↗ |
| Michael MacLean | Director | 2025-07-25 | D | 42,200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alexander Cumbo | Director | 2025-07-25 | D | 136,139 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Troy Lister | Chief Scientific Officer | 2025-07-25 | D | 225,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sekar Kathiresan | Director | 2025-07-25 | D | 488,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jodie Morrison | Director | 2025-07-25 | D | 42,200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Troy Lister | Chief Scientific Officer | 2025-07-25 | D | 6,952 | — | — | Common | Form 4 ↗ |
| Alexander Cumbo | Director | 2025-07-25 | D | 42,200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sheila Mikhail | Director | 2025-07-25 | D | 43,198 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sheila Mikhail | Director | 2025-07-25 | D | 42,200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sheila Mikhail | Director | 2025-07-25 | D | 136,139 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ourania Tatsis | Director | 2025-07-25 | D | 42,200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jason Politi | Chief Technical Ops. Off. | 2025-07-25 | D | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jason Politi | Chief Technical Ops. Off. | 2025-07-25 | D | 16,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jason Politi | Chief Technical Ops. Off. | 2025-07-25 | D | 6,630 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jason Politi | Chief Technical Ops. Off. | 2025-07-25 | D | 40,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andrew Ashe | See Remarks | 2025-07-25 | D | 153,278 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Burt A. Adelman | Director | 2025-07-25 | D | 42,200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Troy Lister | Chief Scientific Officer | 2025-07-25 | D | 69,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Troy Lister | Chief Scientific Officer | 2025-07-25 | D | 6,630 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Troy Lister | Chief Scientific Officer | 2025-07-25 | D | 12,075 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sekar Kathiresan | Director | 2025-07-25 | D | 526,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sekar Kathiresan | Director | 2025-07-25 | D | 99,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sekar Kathiresan | Director | 2025-07-25 | D | 120,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sekar Kathiresan | Director | 2025-07-25 | D | 150,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sekar Kathiresan | Director | 2025-07-25 | D | 110,997 | — | — | Common | Form 4 ↗ |
| Sekar Kathiresan | Director | 2025-07-25 | D | 348,431 | — | — | Common | Form 4 ↗ |
| Joan Nickerson | Chief Administrative Officer | 2025-07-25 | D | 102,016 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Joan Nickerson | Chief Administrative Officer | 2025-07-25 | D | 18,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Joan Nickerson | Chief Administrative Officer | 2025-07-25 | D | 40,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Allison Dorval | Chief Financial Officer | 2025-07-25 | D | 180,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Allison Dorval | Chief Financial Officer | 2025-07-25 | D | 1,875 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Allison Dorval | Chief Financial Officer | 2025-07-25 | D | 33,750 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Allison Dorval | Chief Financial Officer | 2025-07-25 | D | 45,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Allison Dorval | Chief Financial Officer | 2025-07-25 | D | 75,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Krishna Yeshwant | Director | 2025-07-25 | D | 42,200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Krishna Yeshwant | Director | 2025-07-25 | D | 1,800,000 | — | — | Common, indirect | Form 4 ↗ |
| Krishna Yeshwant | Director | 2025-07-25 | D | 4,260,047 | — | — | Common, indirect | Form 4 ↗ |
| Michael MacLean | Director | 2025-07-25 | D | 136,139 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Burt A. Adelman | Director | 2025-07-25 | D | 428,326 | — | — | Common | Form 4 ↗ |
| Sekar Kathiresan | Director | 2025-07-25 | D | 500,203 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Allison Dorval | Chief Financial Officer | 2025-07-25 | D | 258,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andrew Ashe | See Remarks | 2025-07-25 | D | 107,997 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jodie Morrison | Director | 2025-07-25 | D | 267,541 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lonnel Coats | Director | 2025-07-25 | D | 42,200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lonnel Coats | Director | 2025-07-25 | D | 136,139 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Burt A. Adelman | Director | 2025-07-25 | D | 43,198 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Burt A. Adelman | Director | 2025-07-25 | D | 136,139 | — | — | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (107 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Sekar Kathiresan. DEF 14A, filed 2025-04-25. Section “Summary compensation table” · page 17. As printed: 7,442,663. View filing ↗
- Section 01, Andrew Bellinger. DEF 14A, filed 2025-04-25. Section “Summary compensation table” · page 17. As printed: 3,430,900. View filing ↗
- Section 01, Allison Dorval. DEF 14A, filed 2025-04-25. Section “Summary compensation table” · page 17. As printed: 2,881,705. View filing ↗
- Section 01, Andrew Ashe. DEF 14A, filed 2025-04-25. Section “Summary compensation table” · page 17. As printed: 2,380,065. View filing ↗
- Section 03, Andrew Ashe OPTION. DEF 14A, filed 2025-04-25. Section “EXECUTIVE AND DIRECTOR COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Andrew Bellinger OPTION. DEF 14A, filed 2025-04-25. Section “EXECUTIVE AND DIRECTOR COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Sekar Kathiresan PSU. DEF 14A, filed 2025-04-25. Section “EXECUTIVE AND DIRECTOR COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Sekar Kathiresan OPTION. DEF 14A, filed 2025-04-25. Section “EXECUTIVE AND DIRECTOR COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Allison Dorval PSU. DEF 14A, filed 2025-04-25. Section “EXECUTIVE AND DIRECTOR COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Andrew Bellinger PSU. DEF 14A, filed 2025-04-25. Section “EXECUTIVE AND DIRECTOR COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Allison Dorval OPTION. DEF 14A, filed 2025-04-25. Section “EXECUTIVE AND DIRECTOR COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Andrew Ashe PSU. DEF 14A, filed 2025-04-25. Section “EXECUTIVE AND DIRECTOR COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 08, Jodie Morrison. DEF 14A, filed 2025-04-25. Section “Director Compensation”. As printed: 964,970. View filing ↗
- Section 08, Burt Adelman, M.D. DEF 14A, filed 2025-04-25. Section “Director Compensation”. As printed: 568,999. View filing ↗
- Section 08, Michael MacLean. DEF 14A, filed 2025-04-25. Section “Director Compensation”. As printed: 533,999. View filing ↗
- Section 08, Sheila Mikhail, J.D. DEF 14A, filed 2025-04-25. Section “Director Compensation”. As printed: 526,499. View filing ↗
- Section 08, Krishna Yeshwant, M.D. DEF 14A, filed 2025-04-25. Section “Director Compensation”. As printed: 522,667. View filing ↗
- Section 08, Lonnel Coats. DEF 14A, filed 2025-04-25. Section “Director Compensation”. As printed: 521,499. View filing ↗
- Section 08, Alexander Cumbo. DEF 14A, filed 2025-04-25. Section “Director Compensation”. As printed: 521,499. View filing ↗
- Section 08, Sekar Kathiresan, M.D. DEF 14A, filed 2025-04-25. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Ourania Tatsis, Ph.D. DEF 14A, filed 2025-04-25. Section “Director Compensation”. As printed: —. View filing ↗
- Section 02, Krishna Yeshwant 2025-06-05. Form 4, filed 2025-06-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alexander Cumbo 2025-06-05. Form 4, filed 2025-06-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sheila Mikhail 2025-06-05. Form 4, filed 2025-06-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jodie Morrison 2025-06-05. Form 4, filed 2025-06-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael MacLean 2025-06-05. Form 4, filed 2025-06-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Burt A. Adelman 2025-06-05. Form 4, filed 2025-06-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lonnel Coats 2025-06-05. Form 4, filed 2025-06-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ourania Tatsis 2025-06-05. Form 4, filed 2025-06-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Politi 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Politi 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Ashe 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Ashe 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Ashe 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Ashe 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sekar Kathiresan 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sekar Kathiresan 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sekar Kathiresan 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joan Nickerson 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Allison Dorval 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Ashe 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Politi 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sekar Kathiresan 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ourania Tatsis 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Politi 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Ashe 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Troy Lister 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Troy Lister 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sekar Kathiresan 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joan Nickerson 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joan Nickerson 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joan Nickerson 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Krishna Yeshwant 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Krishna Yeshwant 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael MacLean 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alexander Cumbo 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Troy Lister 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sekar Kathiresan 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jodie Morrison 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Troy Lister 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alexander Cumbo 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sheila Mikhail 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sheila Mikhail 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sheila Mikhail 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ourania Tatsis 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Politi 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Politi 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Politi 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Politi 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Ashe 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Burt A. Adelman 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Troy Lister 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Troy Lister 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Troy Lister 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sekar Kathiresan 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sekar Kathiresan 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sekar Kathiresan 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sekar Kathiresan 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sekar Kathiresan 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sekar Kathiresan 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joan Nickerson 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joan Nickerson 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joan Nickerson 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Allison Dorval 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Allison Dorval 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Allison Dorval 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Allison Dorval 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Allison Dorval 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Krishna Yeshwant 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Krishna Yeshwant 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Krishna Yeshwant 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael MacLean 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Burt A. Adelman 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sekar Kathiresan 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Allison Dorval 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Ashe 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jodie Morrison 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lonnel Coats 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lonnel Coats 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Burt A. Adelman 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Burt A. Adelman 2025-07-25. Form 4, filed 2025-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-10. Item 5.07 · say-on-pay result. As reported: 95.33% (votes for as printed: 56,159,136). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-07. Item 5.07 · say-on-pay result. As reported: 87.79% (votes for as printed: 39,396,050). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 408,139 + equity 0 + all other 0 = 408,139, summed across the director compensation table rows.
- Verve Therapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2025-04-25. CEO total compensation as printed in Verve Therapeutics, Inc.'s own proxy. As printed: 7,442,663. View filing ↗